Experimental cell therapy takes on Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage trial is testing a new treatment called CEL001, made from natural killer (NK) immune cells, in 13 people with advanced solid tumors that have not responded to standard therapies. The main goal is to see if the injection is safe and tolerable, while also checking …
Phase: PHASE1 • Sponsor: Guangzhou Xiling Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC